Your browser doesn't support javascript.
loading
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.
Cukierman-Yaffe, Tali; Gerstein, Hertzel C; Basile, Jan; Bethel, M Angelyn; Cardona-Muñoz, Ernesto G; Conget, Ignacio; Dagenais, Gilles; Franek, Edward; Hall, Stephanie; Hancu, Nicolae; Jansky, Petr; Lakshmanan, Mark; Lanas, Fernando; Leiter, Lawrence A; Lopez-Jaramillo, Patricio; Pirags, Valdis; Pogosova, Nana; Probstfield, Jeffrey; Rao-Melacini, Purnima; Ramasundarahettige, Chinthanie; Raubenheimer, Peter J; Riddle, Matthew C; Rydén, Lars; Shaw, Jonathan E; Sheu, Wayne H-H; Temelkova-Kurktschiev, Theodora.
Afiliação
  • Cukierman-Yaffe T; Endocrinology Institute, Sheba Medical Center, Ramat-Gan, and Epidemiology Department, Sackler School of Medicine, Herceg Institute of Aging, Tel Aviv University, Tel Aviv, Israel.
  • Gerstein HC; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
  • Basile J; Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
  • Bethel MA; Eli Lilly and Company, Indianapolis, IN, USA.
  • Cardona-Muñoz EG; CUCS-Universidad de Guadalajara, Mexico.
  • Conget I; Endocrinology and Nutrition Dpt. Hospital Clinic i Universitari, Barcelona, Spain.
  • Dagenais G; Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.
  • Franek E; Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland.
  • Hall S; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
  • Hancu N; Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
  • Jansky P; University Hospital Motol, Prague.
  • Lakshmanan M; Eli Lilly and Company, Indianapolis, IN, USA.
  • Lanas F; Universidad de La Frontera, Temuco, Chile.
  • Leiter LA; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada.
  • Lopez-Jaramillo P; Masira Research Institute, Medical School, Universidad de Santander UDES, Bucaramanga, Colombia.
  • Pirags V; University of Latvia, Pauls Stradins Clinical University Hospital, Riga, Latvia.
  • Pogosova N; National Medical Research Center of Cardiology, Moscow, Russia.
  • Probstfield J; Department of Medicine, University of Washington, Seattle, WA,USA.
  • Rao-Melacini P; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
  • Ramasundarahettige C; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
  • Raubenheimer PJ; Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Riddle MC; Department of Medicine, Oregon Health & Science University Portland, OR, USA.
  • Rydén L; Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.
  • Shaw JE; Baker Heart and Diabetes Institute, Melbourne, Australia.
  • Sheu WH; Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Temelkova-Kurktschiev T; Robert Koch Medical Center, Sofia, Bulgaria.
J Clin Endocrinol Metab ; 107(8): e3448-e3454, 2022 07 14.
Article em En | MEDLINE | ID: mdl-35446415
ABSTRACT
CONTEXT Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationship is stronger using novel cognitive indices is unknown.

METHODS:

Participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial who completed both the Montreal Cognitive Assessment (MoCA) score and Digit Substitution Test (DSST) at baseline (N = 8772) were included. These scores were used to identify participants with baseline substantive cognitive impairment (SCI), defined as a baseline score on either the MoCA or DSST ≥ 1.5 SD below either score's country-specific mean, or SCI-GM, which was based on a composite index of both scores calculated as their geometric mean (GM), and defined as a score that was ≥ 1.5 SD below their country's average GM. Relationships between these measures and incident major adverse cardiovascular events (MACE), and either stroke or death were analyzed.

RESULTS:

Compared with 7867 (89.7%) unaffected participants, the 905 (10.3%) participants with baseline SCI had a higher incidence of MACE (unadjusted hazard ratio [HR] 1.34; 95% CI 1.11, 1.62; P = 0.003), and stroke or death (unadjusted HR 1.60; 95% CI 1.33, 1.91; P < 0.001). Stronger relationships were noted for SCI-GM and MACE (unadjusted HR 1.61; 95% CI 1.28, 2.01; P < 0.001), and stroke or death (unadjusted HR 1.85; 95% CI 1.50, 2.30; P < 0.001). For SCI-GM but not SCI, all these relationships remained significant in models that adjusted for up to 10 SCI risk factors.

CONCLUSION:

Country-standardized SCI-GM was a strong independent predictor of cardiovascular events in people with type 2 diabetes in the REWIND trial.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Acidente Vascular Cerebral / Diabetes Mellitus Tipo 2 / Disfunção Cognitiva Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Acidente Vascular Cerebral / Diabetes Mellitus Tipo 2 / Disfunção Cognitiva Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel